How to use Dabrafenib (Teferal)? What is the clinical effect?

Dabrafenib (Dabrafenib) is an oral small molecule BRAF kinase inhibitor, mainly used to treat BRAF V600E or V600K mutation-positive melanoma, non-small cell lung cancer and other solid tumors. It is administered orally, usually twice a day. Each dose must follow the doctor's prescription and be individually adjusted based on the patient's weight, liver and kidney function, and combined medication. When taking the medicine, the tablet should be swallowed whole and should not be chewed or crushed. It is also recommended to take it at a fixed time to maintain stable blood concentration. Patients need to regularly review their blood, liver and kidney function and skin conditions during medication to monitor drug tolerance and potential adverse reactions.

In terms of clinical effects, dabrafenib can prevent tumor cell proliferation and induce apoptosis by inhibiting the MAPK signaling pathway activated by the BRAF V600 mutation. In multiple clinical trials, dabrafenib alone or in combination with MEK inhibitors has shown a high overall response rate (ORR), and some patients can obtain complete remission (CR). The therapeutic effect is usually observable within weeks to months of medication, but the specific efficacy is affected by individual patient differences, tumor type and disease course.

Dabrafenib has shown a significant survival benefit in the treatment of melanoma and can prolong the median progression-free survival (PFS) and overall survival (OS). In patients with non-small cell lung cancer, dabrafenib combined with trametinib also showed better efficacy than monotherapy. In clinical practice, doctors will develop individualized treatment plans based on the patient's genetic mutation status and overall health to maximize efficacy and reduce the risk of adverse reactions.

Patients should pay attention to common side effects while using dabrafenib, including rash, fever, fatigue, joint pain, and abnormal liver function. For symptoms such as fever, you should seek medical treatment promptly and adjust the dose or suspend medication if necessary. Long-term medication also requires monitoring of electrocardiogram, blood pressure and fundus conditions to prevent serious complications. Overall, dabrafenib, as a targeted therapy drug, provides an important treatment option for patients with BRAF mutation-related tumors with its clear target mechanism and good efficacy.

Reference materials:https://www.drugs.com/